HIGHLIGHTS
- who: Helena Iznardo and collaborators from the Dermatology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, Barcelona, Spain have published the research: Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis, in the Journal: Pharmaceutics 2023, 15, 385. of /2023/
- what: Treatment with abrocitinib has been demonstrated to be efficacious and safe in clinical trials with selected AD patients.
- how: Showed that JAK inhibitors present comparable safety profiles statistically significant differences were observed only when compared with placebo or dupilumab .
SUMMARY
By week 12, clear . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.